The Committee backed the combination based on results from the CAPItello-281 Phase III trial, marking a key milestone in the regulatory pathway for AstraZeneca’s targeted therapy strategy in prostate cancer
The company’s Growth Portfolio delivered $6.2 billion in revenue
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 3 to 6 against recommending camizestrant in combination with a CDK4/6 inhibitor
The move puts a spotlight on one of psychiatry’s most persistent clinical challenges: misdiagnosis and delay
Stroke is the second-leading cause of death and the third-leading cause of disability worldwide
Under the terms, Arcellx shareholders received $115 per share in cash plus a non-transferable contingent value right
The 4,000-square-foot facility is designed as a hands-on hub where customers can work directly with scientists and engineers
But acquisition charges drag earnings into loss
While Drugs for Neglected Diseases initiative (DNDi) drives the R&D for neglected diseases, we collaborate with pharmaceutical companies at multiple stages, including sourcing promising molecules
Subscribe To Our Newsletter & Stay Updated
